WEB Estrogen Conjugated Silica-coated Gold Nanoparticles for In vivo Targeting of Breast Cancer CellsTuesday (22.09.2020) 16:10 - 16:25 B: Biomaterials Part of:
Despite remarkable progress in medical research, cancer belongs to the top three death cause worldwide due to the lack of sensitive strategies for targeted transport and receptor-mediated uptake of synthetic drug molecules by cancer cells. To fill this gap of knowledge, nanotechnology developed into a promising field in cancer research by using nanomaterials loaded with different biomolecules and imaging agents contribute to the improved delivery of drug at the target site and minimizing its exposure to the healthy tissues. In this context, gold nanoparticles came into the main focus of cancer research over the last decades and offer high surface plasmonic resonance leading to optothermal behavior in the near infrared area, being chemically inert and non-toxic to the human body. Nevertheless, nanoparticles in cancer therapy remains as an immense challenge to ensure a highly specific uptake of nanoparticles for cancer cells.
We present here an active targeting strategy based on the conjugation of specific targeting ligand on gold nanorods encapsulated with mesoporous silica shell (mSiO2@Au: length of 40 nm, width 20 nm). The vectorization of here developed nanocarriers was achieved by grafting an estrogen molecule beside loading of anticancer drug doxorubicine that facilitated intracellular transport of nanocarriers verified by selective uptake and targeted delivery in estrogen overexpressing cancer cell line. In addition, the chemoselective recognition between the nano-conjugates and cell membranes was successfully demonstrated by the preferential accumulation of nanoprobes in the tumor tissue of mice with subcutaneous breast cancer, which was quantified by FACS analysis. Chemical and structural analysis of the bioconjugates examined in solution (UV-Vis, ξ-potential) and solid-state (FTIR, XRD, TEM) confirmed the identity of the carrier particles and surface-bound ligands. Our data shows, that as-prepared nanoconjugates hold potential to be used as targeting specific drug delivery nanoprobes for breast cancer research.